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J
ust weeks after the September 11
terrorist attacks in New York
and Washington, letters containing
anthrax spores were mailed to news-
papers and television stations in
New York and to two U.S. senators
on Capitol Hill. Although only a
few letters were sent, 22 people were
infected and 5
died. More im-
portantly, the
bioterror attacks
fueled fears that
future attacks
might be more
extensive. Now
researchers at
the University of
Central Florida
are helping to prepare for the possi-
bility of anthrax attacks by develop-
ing a new technique that can quickly
produce hundreds of millions of
doses of a potentially safer anthrax
vaccine.
Since the 1960s American micro-
biologists have produced a vaccine
for anthrax from the very microbe
itself,  Bacillus anthracis. The
microbe’s toxin is made up of three
key parts: edema factor (EF), lethal
factor (LF), and protective antigen
(PA). EF causes fluid to build up in
the area of infection, while LF kills
cells or prevents them from working.
However, both of these factors
require PA to
create a pas-
sageway into
the cells—the
PA bonds to
protein recep-
tors, creating a
new complex
to which the
other two fac-
tors attach.
According to Stephen Leppla, a
senior researcher at the National
Institute of Allergy and Infectious
Diseases (NIAID), anthrax bacteria
that don’t have PA cannot cause an
infection. “In essence,” he says,
“they are inactivated and become
much less virulent.” The current
anthrax vaccine works on this very
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the event of a future anthrax exposure
would be inactivated by these antibodies,
stopping the infection in its tracks.
In Pursuit of PA
But obtaining large quantities of PA has
been a problem. Only one company—
BioPort of Lansing, Michigan—is
licensed by the FDA to produce the vac-
cine in the United States, and it can pro-
duce only 8 million doses each year
through a fermentation process, according
to BioPort spokeswoman Kimberly
Brenne Root. That’s enough to fill the
company’s contracts with the Department
of Defense (DOD) and the Department
of Health and Human Services, which
stockpile the vaccine and administer it to
military personnel, but not enough to
vaccinate a large civilian population in the
event of a widespread attack.
In 2004, in an attempt to procure
more doses of vaccine, the U.S. govern-
ment awarded an $877.5-million contract
to VaxGen of Brisbane, California, to
produce 75 million doses by the end of
2006. Setbacks have resulted in major
delays, however; on 10 May 2006, com-
pany officials confirmed that the first
shipments of the vaccine won’t be deliv-
ered before late 2007 at the very soonest.
As well, there have been concerns that
the vaccine produced by BioPort was not
safe. Several Gulf War service members
reported health problems after being vacci-
nated. Anecdotal reports suggest the vac-
cine may contribute to heart problems,
cardiovascular illness, seizures, Gulf War
syndrome, even death. Documented side
effects include pain and swelling at the
injection site, inflammation, flu-like symp-
toms, malaise, rash, joint pain, and
headache. The BioPort vaccine can be con-
taminated with small amounts of LF and
EF, which may contribute to the adverse
effects associated with it.
To overcome these problems, Henry
Daniell, a professor of molecular biology
and microbiology at the University of
Central Florida, has been on the hunt for
a way to produce large quantities of
“clean” PA, free of EF and LF. Now he
thinks he has finally found it.
Turning Over a New Leaf
Daniell and his team began by isolating the
gene for PA from B. anthracis. Then they
inserted the gene into tobacco plants.
“There are a lot of advantages to tobacco
plants,” says Daniell. “They produce a lot
of biomass. . . . Also, we didn’t want to
produce a vaccine in a food crop in case
there was cross-contamination or some
package got mixed up on some truck
somewhere.” (Although tobacco shipments
also could get mixed up, burning the
tobacco in the course of smoking would
destroy the PA it contained.) Furthermore,
Daniell says, “[Tobaccco plants] are very
easy to genetically manipulate.”
Daniell’s team chose to insert the gene
into the chloroplast rather than the cell
nucleus since they could get far more
copies of the PA protein that way. After
harvesting the tobacco plants, Daniell’s
team found that each plant produced
about 150 milligrams of anthrax PA. That
adds up to 360 million doses’ worth of
PA from one acre of tobacco plants. And
because only PA is produced, the result-
ing vaccine will be cleaner than one pro-
duced through fermentation. 
When the PA was introduced into
mice, the rodents responded by produc-
ing very high levels of anti-PA antibodies.
The immunized mice were sent to the
NIAID, where they underwent anthrax
toxin challenge. There, Leppla injected
the mice with 150 micrograms of anthrax
toxin, 1.5 times the amount needed to
kill a mouse. Yet, the mice survived, prov-
ing that the new technique could produce
an effective vaccine. These findings were
published in the December 2005 issue of
Infection and Immunity.
Practical Considerations
Rakesh Bhatnagar, chairman of the
Centre for Biotechnology at Jawaharlal
Nehru University in New Delhi, India,
has researched plant-based anthrax vac-
cines, and has signed a commercial agree-
ment to produce larger quantities of
anthrax PA than BioPort while still using
a fermentation system. He believes
Daniell’s research is significant because it
shows that PA produced in plants can
protect animals from anthrax. Yet he also
believes plant-based vaccines still belong
to the future. 
“At this point in the road [plant-based
vaccine researchers] have only expressed
the protein in a few plants and only tested
on small animals,” says Bhatnagar. “Plant
vaccines are a long way off, because
industry wants higher levels of productiv-
ity to be successful. Plus, everything
requires approval from government regu-
lators, so it all takes time. But, if I had to
estimate, it might be ten years down the
road.”
Daniell disagrees with this assessment,
however. He says that vaccines against
agents of bioterrorism are now on fast-
track approval, and approval should come
much sooner than 10 years. 
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Fighters first, but then what? The government has stockpiled enough anthrax vaccine
to supply military personnel but not nearly enough for public citizens. (above) Monica
Carpenter, a medical services journeyman in the U.S. Air Force, administers anthrax vac-
cine to Technical Sergeant Ricky Anderson in Iraq.
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remain anonymous, says that a plant-
based anthrax vaccine would be of interest
but that such a vaccine would have to be
approved by the FDA. Also, says the
spokesperson, “At present, the DOD has
sufficient FDA-licensed anthrax vaccine
to fulfill its policy. If the supply of
anthrax vaccine was suddenly expanded,
it might be that civilian purchasers of the
vaccine would be less constrained than at
present.”
A Growth Industry?
Meanwhile, Daniell and his team aren’t
content with producing 360 million doses
of anthrax vaccine. Rather, they consider
this a preliminary step towards an even
greater goal: vaccines that are actually
grown in and consumed along with a
piece of fruit.
The idea of putting vaccines in plants
or fruits was pioneered in 1992 by Charles
Arntzen, currently codirector of the Center
for Infectious Disease and Vaccinology at
Arizona State University, after he observed
a mother feeding her child a banana during
a research trip to Thailand. Arntzen’s idea
was simple: what if we could cut through
the obstacles to vaccination by simply
growing vaccines in fruit? 
Many vaccines are hard to produce
because of expensive fermenters, hard to
ship because they often need to be kept
refrigerated, and hard to distribute widely
because it can take a trained health pro-
fessional to administer the vaccine. All
these factors make it particularly difficult
to vaccinate populations in developing
countries. Arntzen and his colleagues have
continued exploring this line of think-
ing, and in the 1 March 2005 issue of
Proceedings of the National Academy of
Sciences, they conclude that a plant-based
oral vaccine against hepatitis B, as deliv-
ered via potato, “should be considered as
a viable component of a global immuniza-
tion program.” 
However, before we can eat bananas or
potatoes for our booster shots, researchers
need to figure out a few key problems.
First, there needs to be a way to stan-
dardize the vaccine’s dose. “Other vaccines
are very exact on the dosages,” says Bhat-
nagar, “but with plant-based vaccines,
what are you going to say? In the plant,
levels might vary widely.” 
The other major problem is that it
takes months for a crop to grow, even a
quick-growing one like tobacco, whereas
the bacteria used in a fermentation system
take only days or even hours. On the
other hand, a crop system could be cheap-
er and produce more vaccine, compared
to a fermentation system.
Despite the remaining hurdles, Daniell
believes that his developments in tobacco
plants will lead to an anthrax vaccine
someday in the future. His team is also
working on growing vaccine antigens
against other diseases such as cholera,
amebiasis, plague, and hepatitis C in
tobacco plants.
“If a vaccine was produced in a plant
cell, dried cells could be put in a capsule
and delivered because the plant cell wall
protects the protein already,” says Daniell.
“Different delivery methods still need
approval, but the cost of vaccines could
drop from [up to] a hundred dollars to a
few cents since basically all you are doing is
powdering the plant and putting it in a
capsule. For that reason, it is worth every
regulatory hurdle, because it will pay off
big time.”
Graeme Stemp-Morlock
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Sleeping giant? Although no one can predict if, when, or where an anthrax outbreak
might occur, the magnitude of the threat makes the development of adequate vaccine
resources a priority. (above) Bacillus anthracis spores in lung tissue.
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